PGP and cancer: Tubulin inhibitors targeting the colchicine siteare candidates for better clinical outcomes,29,30 being less vulnerable to Pgp overexpression than other antitubulinagents31,32 and being active against cancer cells overexpressingβ3-tubulin.29